Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis.
Kontou-Fili
K
K
Chief Allergology Department, Euroclinic Hospital, Athens, Greece. kontoufk@otenet.gr
Filis
C I
CI
D000328:Adult; D000707:Anaphylaxis / Q000276:immunology / Q000517:prevention & control*; D018926:Anti-Allergic Agents / Q000008:administration & dosage*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D001514:Bee Venoms / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008415:Mastocytosis / Q000628:therapy*; D000069444:Omalizumab; D053802:Tryptases / Q000097:blood
D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001514:Bee Venoms; D000069444:Omalizumab; D053802:Tryptases